Elimination of Mother-to-Child Transmission HIV, Hepatitis B and Syphilis in Asia and the Pacific
Countries that have achieved EMTCT validation
Thailand
Thailand was the first country in Asia and the Pacific region to achieve EMTCT validation for HIV. Thailand reached this important milestone in June 2016.
>> View publications and resources
>> Country Overview Slides
Malaysia
Malaysia was the second country in Asia and the Pacific region to achieve EMTCT validation status for HIV in October 2018.
>> View publications and resources
>> Country Overview Slides
Maldives
>> Country Overview Slides
Maldives was the 3rd country in Asia and the Pacific region to achieve EMTCT validation status for HIV in July 2019.
>> View publications and resources>> Country Overview Slides
Sri Lanka
Sri Lanka became the 4th country in Asia and the Pacific region to achieve EMTCT validation status for HIV, having done so in November 2019.
>> View publications and resources
>> Country Overview Slides
Country achievements at the time of EMTCT validation
| Impact/Process indicator | Achievement |
| Percentage of pregnant women attending antenatal care at least once (ANC1) | 98.3 % |
| Percentage of pregnant women with known HIV status (includes both newly tested and those with known status) | 99.6 % |
| Percentage of antenatal care (ANC) attendees tested for HBsAG | na |
| Percentage of women accessing ANC who were tested for syphilis | 99.1 % |
| Percentage of pregnant women living with HIV who received antiretroviral therapy (ART) | 95.6 % |
| Percentage of pregnant women living with positive syphilis serology who were treated adequately | 95.9 % |
| Percentage of infants receiving a birth dose of hepatitis B vaccine (HepB-BD) | na |
| Coverage of hepatis B vaccine third dose (HepB3) among infants | na |
| Impact/Process indicator | Achievement |
| Percentage of pregnant women attending antenatal care at least once (ANC1) | 98% |
| Percentage of pregnant women with known HIV status (includes both newly tested and those with known status) | 98% |
| Percentage of antenatal care (ANC) attendees tested for HBsAG | na |
| Percentage of women accessing ANC who were tested for syphilis | 100% |
| Percentage of pregnant women living with HIV who received antiretroviral therapy (ART) | No case |
| Percentage of pregnant women living with positive syphilis serology who were treated adequately | 100% |
| Percentage of infants receiving a birth dose of hepatitis B vaccine (HepB-BD) | na |
| Coverage of hepatis B vaccine third dose (HepB3) among infants | na |
| Impact/Process indicator | Achievement |
| Percentage of pregnant women attending antenatal care at least once (ANC1) | 96.7 % |
| Percentage of pregnant women with known HIV status (includes both newly tested and those with known status) | 95.8 % |
| Percentage of antenatal care (ANC) attendees tested for HBsAG | na |
| Percentage of women accessing ANC who were tested for syphilis | 95.8 % |
| Percentage of pregnant women living with HIV who received antiretroviral therapy (ART) | 97.5 % |
| Percentage of pregnant women living with positive syphilis serology who were treated adequately | 100 % |
| Percentage of infants receiving a birth dose of hepatitis B vaccine (HepB-BD) | na |
| Coverage of hepatis B vaccine third dose (HepB3) among infants | na |
| Impact/Process indicator | Achievement |
| Percentage of pregnant women attending antenatal care at least once (ANC1) | 96.4 % |
| Percentage of pregnant women with known HIV status (includes both newly tested and those with known status) | 95.9 % |
| Percentage of antenatal care (ANC) attendees tested for HBsAG | na |
| Percentage of women accessing ANC who were tested for syphilis | 99.3 % |
| Percentage of pregnant women living with HIV who received antiretroviral therapy (ART) | 100 % |
| Percentage of pregnant women living with positive syphilis serology who were treated adequately | 97.2 % |
| Percentage of infants receiving a birth dose of hepatitis B vaccine (HepB-BD) | na |
| Coverage of hepatis B vaccine third dose (HepB3) among infants | na |